Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

Data ReadoutAzenosertibPositive

AI Analysis

Summary

Zentalis announced that first overall survival data for azenosertib from the DENALI Part 1b trial were published in an ESMO Congress 2026 abstract. The article text provides no specific efficacy results.

Clinical Trial Data

Phase

Phase_2

Outcome Details

First overall survival data for azenosertib from DENALI Part 1b published in an ESMO Congress 2026 abstract; specific results not provided in the article text.

Importance:5/10

Sentiment:

0.30

ESMO 2026overall survivalDENALIazenosertiboncologyabstract

Related Companies

$ZNTL

Read the original article

Published by yahoo_finance on October 18, 2026 10:05 PM

Read Original